**Tabel 1.** Data Demografi Pasien HIV Rawat Jalan (n=72)

|  |  |
| --- | --- |
| n (%) | |
| **Jenis Kelamin** |  |
| *Laki-Laki* | 63 (87) |
| *Perempuan* | 9 (13) |
| **Usia (Tahun)** |  |
| *Rentang*  *Rata-rata ± SD* | *17-53*  29,9 ± 8,9 |
| **Kategori Usia** |  |
| *Remaja Akhir (17-25)* | 33 (46) |
| *Dewasa Awal (26-35)* | 21 (29) |
| *Dewasa Akhir (36-45)* | 12 (17) |
| *Lansia Awal (46-55)* | 6 (8) |
| **Status Pasien** |  |
| *Pasien Baru* | 2 (3) |
| *Pasien Lama* | 70 (97) |
| **ARV lini pertama** |  |
| *FDC (Efavirenz 600 mg, Lamivudin 300 mg, Tenofovir 300 mg)* | 63 (57) |
| *Efavirenz 600 mg, Lamivudin 150 mg, Tenofovir 300 mg)* | 34 (31) |
| *Duviral (Zidovudin+Lamivudin)–Neviral (Nevirapin)* | 13 (12) |
| **Lama Terapi ARV** |  |
| *1 Minggu – 5 Bulan* | 13 (18) |
| *6 Bulan – 12 Bulan* | 18 (25) |
| *>1 Tahun* | 41 (57) |

**Tabel 2.** Profil Penyakit Infeksi Oportunistik Pada Pasien HIV (n=13)

|  |  |  |
| --- | --- | --- |
| **No.** | **Infeksi Oportunistik** | **n (%)** |
| 1 | Tuberkulosis Paru | 8(61) |
| 2 | Pneumocystis Pneumonia (PCP) | 2(15) |
| 3 | Tuberkulosis Ekstra Paru | 1(8) |
| 4 | Sifilis | 1(8) |
| 5 | Kandidiasis Oral | 1(8) |

**Tabel 3.** Profil Obat Untuk Infeksi Oportunistik

|  |  |  |
| --- | --- | --- |
| No. | Obat | n (%) |
| 1. | FDC fase intensif (Rifampisin 150mg, Isoniazid 75mg, Pyrazinamide 400mg, Ethambutol HCl 275mg) dan FDC fase lanjutan (Rifampisin 150mg, Isoniazid 150mg) | 9 (69) |
| 2. | Cefixime dan Cotrimoxazole Forte | 2 (15) |
| 3. | Injeksi Penicillin G Procain, Erythromycin Stearate 500mg, dan Doxycycline | 1 (8) |
| 4. | Fluconazole | 1 (8) |

**Tabel 4.** Penggantian Terapi ARV

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **No** | **Obat ARV** |  | **Obat ARV** | **n (%)** |
| 1 | FDC (Efavirenz 600mg, Lamivudin 300mg, Tenofovir 300mg) | 🡪 | Duviral-Neviral | 3 (25) |
| 2 | Duviral-Neviral | 🡪 | FDC (Efavirenz 600mg, Lamivudin 300mg, Tenofovir 300mg) | 9 (75) |

**Tabel 5.** Profil Efek Samping Obat ARV Lini Pertama

|  |  |  |
| --- | --- | --- |
| **No.** | **Jenis ESO** | **n (%)** |
| 1 | Pusing | 56 (46) |
| 2 | Mual dan Muntah | 41 (33) |
| 3 | Ruam | 15 (12) |
| 4 | Halusinasi | 5 (4) |
| 5 | Mengantuk | 4 (3) |
| 6 | Sakit Kepala | 1 (1) |
| 7 | Mimpi Buruk | 1 (1) |

**Tabel 6.** Hasil Skala Naranjo

|  |  |  |
| --- | --- | --- |
| No | Skala Naranjo | n (%) |
| 1 | *Highly Probable (>9)* | 1 (1) |
| 2 | *Probable (5-8)* | 62 (86) |
| 3 | *Possible (1-4)* | 9 (13) |

**Tabel 7.** Perbedaan Skor Naranjo Pada Pasien HIV Dengan dan Tanpa Infeksi Oportunistik

|  |  |  |  |
| --- | --- | --- | --- |
| **Kategori Naranjo** | **Dengan IO**  n(%) | **Tanpa IO**  n(%) | **α** |
| *Highly Probable* (≥9) | - | 1 (2) | 0,004 |
| *Probable* (5-9) | 7 (54) | 55 (93) |
| *Posible* (1-4) | 6 (46) | 3 (5) |
| **Rata-rata ± SD** | 4 ± 1,7 | 6 ± 1,2 |

**Tabel 8.** Perbedaan Skor Naranjo Pada Pasien HIV Dengan dan Tanpa Penyakit Penyerta

|  |  |  |  |
| --- | --- | --- | --- |
| **Kategori Naranjo** | **Dengan Penyakit Penyerta**  n(%) | **Tanpa Penyakit Penyerta**  n(%) | **α** |
| *Highly Probable* (≥9) | - | 1 (2) | 0,003 |
| *Probable* (5-9) | 4 (57) | 58 (89) |
| *Posible* (1-4) | 3 (43) | 6 (9) |
| **Rata-rata ± SD** | 4 ± 1, 6 | 6 ± 1,2 |